Peter Olagunju
Chief Operating Officer at TCR2 THERAPEUTICS INC.
Profile
Peter Olagunju is currently the Chief Operating Officer at TCR2 Therapeutics, Inc. He previously worked as the Head-Quality at Dendreon Corp.
and ZymoGenetics, Inc. From 2015 to 2020, he served as the Vice President-Global Patient Operations at bluebird bio, Inc. and from 2020 to 2021, he was the Senior Vice President-Technical Operations at FerGene, Inc. Mr. Olagunju holds an MBA from the University of Washington and an undergraduate degree from the University of Illinois At Urbana–Champaign.
Peter Olagunju active positions
| Companies | Position | Start |
|---|---|---|
| TCR2 THERAPEUTICS INC. | Chief Operating Officer | 31/12/2022 |
Former positions of Peter Olagunju
| Companies | Position | End |
|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/07/2021 |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/03/2020 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
| DENDREON CORPORATION | Corporate Officer/Principal | - |
Training of Peter Olagunju
| University of Washington | Masters Business Admin |
| University of Illinois At Urbana–Champaign | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| Private companies | 4 |
|---|---|
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Peter Olagunju
